-
Sanjitang glimepiride was disqualified from being selected as a substitute for Conquer Pharmaceuticals
Time of Update: 2022-05-02
On February 23, Shanghai Sunshine Pharmaceutical Purchasing Network issued an announcement saying that the glimepiride tablets produced by Shengjitang had been disqualified from the second batch of national procurement due to non-compliance with the quality management standards for drug production.
-
Panoramic Interpretation of China's Clinical Trial Application Trends in 2021
Time of Update: 2022-05-02
During this period, the number of core clinical trials carried out in the United States has stabilized at more than 200 per year, while the core clinical development of Chinese companies has increased rapidly since 2017.
-
Embarrassing 1.2 new Chinese medicines
Time of Update: 2022-05-02
” This point of view is a good description of the different research and development paths of traditional Chinese medicine compound preparations and innovative drugs 1.
2 new traditional Chinese medicines are approved in accordance with the current drug registration management measures.
-
Intellia and Regeneron Announce Latest Phase 1 Clinical Trial Data of NTLA-2001
Time of Update: 2022-05-02
The results showed that all doses administered were well tolerated, with mean 86% and 93% reductions in serum levels of the target protein in the two highest dose groups, respectively .
-
78 drugs from 21 pharmaceutical companies took the initiative to cut prices, with a drop of over 60%!
Time of Update: 2022-05-02
On February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued a public announcement about companies applying for price reductions .
7ml:100mg and 5ml:30mg specifications of Huiyu Pharmaceutical's paclitaxel injection have been greatly reduced in price, of which the 16.
-
Another pharmaceutical company discloses 2021 annual performance forecast
Time of Update: 2022-05-02
The performance forecast released by GenScript Biotechnology shows that in fiscal 2021, the adjusted net profit of the group business (non-cell therapy business) excluding the subsidiary Legend Biotechnology was about US$48 million to US$51.
-
The abuse of antibiotics at the grassroots level is more than the harm of the abuse of antibiotics?
Time of Update: 2022-05-02
Moxifloxacin, as a fourth-generation quinolone broad-spectrum antibacterial drug, has been mainly used in large hospitals for patients with pulmonary infection in recent years, that is, when ordinary antibiotics are ineffective .
But this patient was only on moxifloxacin for a common upper respiratory tract infection .
-
Chengdu Beite Calcium Gluconate Injection passed the consistency evaluation of generic drugs
Time of Update: 2022-05-02
Data source: Minet database, CDE On February 24, NMPA's official website showed that Chengdu Better Pharmaceutical's calcium gluconate injection passed the consistency evaluation of generic drugs, which was the first domestic review .
-
The transformation of the pharmacy industry is accelerating, and the development of diversification and specialization has become the general trend
Time of Update: 2022-05-02
Enterprises have been determined to carry out the pilot work of comprehensive reform of large chain convenience stores operating only Class B non-prescription drugs in the whole province .
As early as 2020, it issued an announcement stating that the company and its wholly-owned subsidiary Hainan Hongxiang Yixintang Pharmaceutical Chain Co.
-
Pharmaceutical companies are strengthening domestic substitution of upstream equipment, and the pharmaceutical machine industry may benefit
Time of Update: 2022-05-02
For this cooperation, the industry believes that, in addition to speeding up the integrated competitiveness of the research and development, production and sales of Kangfang biopharmaceuticals, it is also a manifestation of domestic innovative pharmaceutical companies strengthening the independent controllability of the supply chain and domestic substitution .
-
Shuanghe Pharmaceutical, a wholly-owned subsidiary of China Resources Double Crane, passed the CDE technical review for the API of ticagrelor
Time of Update: 2022-05-02
On February 23, China Resources Double-Crane announced that its wholly-owned subsidiary, Double-Crane Pharmaceutical Co. , Ltd. , passed the technical review of the Drug Evaluation Center of the State
-
More than 240 pharmaceutical companies have disclosed performance forecasts, with dazzling net profits concentrated in the fields of vaccines and testing
Time of Update: 2022-05-02
. In addition to Zhifei Bio and CanSino, the net profit of vaccine companies such as Olin Bio and Kangtai Bio is also expected to increase significantly year-on-year in 2021.
-
CDE Publishes Guidelines for Mixing Uniformity and Intermediate Control Dose Uniformity of Chemical Drug Solid Preparations
Time of Update: 2022-05-02
On February 18, the CDE official website issued an announcement stating that in order to guide the research on the mixing uniformity of chemical oral solid preparations and the uniformity of the medi
-
Jiangxi Provincial Food and Drug Administration issued a notice to further strengthen the production management of Chinese herbal medicine pieces
Time of Update: 2022-05-02
In order to further improve and strengthen our province's Fresh Bamboo Lek Chinese herbal medicine pieces, ensure clinical efficacy, prevent product quality risks, and enhance the brand value of Gan-produced Chinese herbal medicine pieces, we are now in accordance with the "Pharmaceutical Administration Law of the People's Republic of China" and the "Measures for the Supervision and Administration of Drug Production", etc.
-
Pharmaceutical companies are robbing people by "involution"!
Time of Update: 2022-05-02
The continuous enhancement of the competitiveness of local pharmaceutical companies has formed a strong attraction for overseas R&D talents; pharmaceutical companies, including traditional pharmac
-
Antibacterial preparations illegally added to drugs?
Time of Update: 2022-05-02
For these outstanding problems, the Supreme People's Procuratorate requires, on the one hand, to urge the drug safety supervision department to perform its supervision and management duties in accordance with the law through administrative public interest litigation; Violators are liable for punitive damages, making them so painful that they dare not commit the crime again .
-
CD30-targeted drug Adcetris combined with chemotherapy: first-line treatment significantly prolongs survival!
Time of Update: 2022-05-02
ECHELON-1 is a randomized, open-label, international phase 3 study in adults with newly diagnosed advanced (stage III or IV) cHL to compare Adcetris combined with chemotherapy AVD (doxorubicin + vincristine) Efficacy and safety of ABVD (doxorubicin + bleomycin + vincristine + dacarbazine) relative to the currently accepted standard-of-care regimen ABVD (doxorubicin + bleomycin + vincristine + dacarbazine) .
-
Medical companies are setting off a wave of listing in Hong Kong!
Time of Update: 2022-05-02
However, it should be noted that under the background of the current medical enterprises getting together to list in Hong Kong, there are many medical companies that have failed to go public due to the expiration of their prospectus .
-
The "industry + business" cooperation model is emerging in the pharmaceutical industry
Time of Update: 2022-05-02
For these cooperations, the industry believes that commercial companies will bring a broader sales market to their products with the help of the mature distribution system and channel terminal layout and development of Jointown .
-
The Health and Health Commission issued a document: Restrict the use of imported medical consumables!
Time of Update: 2022-05-02
Improve the recruitment mechanism and promote the substitution of domestic consumables The Guangdong Provincial Medical Insurance Bureau stated that in the future, it will establish and improve the coordination mechanism for medical insurance payment standards and centralized procurement of medical consumables.
